Wiener Neudorf, Austria

Maria O'Rourke


 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 11(Granted Patents)


Location History:

  • Vienna, AT (2014)
  • Wiener Neudorf, AT (2014 - 2022)

Company Filing History:


Years Active: 2014-2022

Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Maria O'Rourke: Innovator in Lyme Disease Vaccine Development

Introduction

Maria O'Rourke is a prominent inventor based in Wiener Neudorf, Austria. She has made significant contributions to the field of biotechnology, particularly in the development of vaccines. With a total of six patents to her name, O'Rourke's work focuses on innovative solutions for health challenges.

Latest Patents

One of her latest patents involves the development of chimeric OspA genes, proteins, and methods of use thereof. This invention relates to creating chimeric OspA molecules intended for a new Lyme vaccine. The chimeric OspA molecules consist of the proximal portion from one OspA serotype and the distal portion from another OspA serotype, while retaining the antigenic properties of both parent polypeptides. These molecules can be delivered alone or in combination to provide protection against various genospecies. Additionally, the invention outlines methods for administering these chimeric OspA molecules to subjects for the prevention and treatment of Lyme disease or borreliosis.

Career Highlights

Throughout her career, Maria O'Rourke has worked with notable companies such as Baxalta GmbH and Brookhaven Science Associates, LLC. Her experience in these organizations has contributed to her expertise in vaccine development and biotechnology.

Collaborations

O'Rourke has collaborated with several professionals in her field, including Brian A. Crowe and Ian Livey. These collaborations have likely enhanced her research and development efforts in creating effective health solutions.

Conclusion

Maria O'Rourke stands out as an innovative inventor dedicated to advancing vaccine technology. Her work in developing chimeric OspA molecules represents a significant step forward in combating Lyme disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…